Story

Spyre Therapeutics Shares Fall After Rheumatoid Arthritis Drug Fails to Meet Internal Efficacy Bar

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Spyre Therapeutics Shares Fall After Rheumatoid Arthritis Drug Fails to Meet Internal Efficacy Bar
Text size
Background

Shares of Spyre Therapeutics (NASDAQ: SYRE) fell sharply in pre-market trading after the company announced it will not advance its anti-TL1A antibody candidate, SPY072, as a standalone therapy for rheumatoid arthritis. The decision came after topline data from a Phase 2 trial showed the drug's effect did not meet the company's internal threshold for progression in this specific indication.

Trial Data Disappoints

Spyre reported data from the rheumatoid arthritis portion of its Phase 2 SKYWAY basket trial, where SPY072 was evaluated against a placebo. While both tested doses achieved statistical significance on at least one efficacy endpoint, the overall results were not strong enough to warrant pursuing it as a monotherapy.

Key findings from the trial include:

  • The high dose of SPY072 demonstrated a 63% ACR20 response rate, a standard measure of symptom improvement in rheumatoid arthritis.
  • This compared to a 43% response rate for patients receiving a placebo.

Despite this improvement over placebo, the company stated that the overall magnitude of the effect was insufficient to prioritize SPY072 as a standalone treatment for the condition, leading to the halt of its development for this specific use.

Market Reaction and Outlook

The stock slid 11.7% in pre-open trading as investors reacted to the disappointing outcome for what was considered a significant near-term catalyst. The sell-off was specific to the company's clinical news, as the broader S&P 500 was nearly flat.

Sample IUX Markets – In-articleAd

However, some analysts maintained a positive long-term view. Wedbush, for example, reiterated its Outperform rating and a $130 price target on the stock, according to Investing.com. This suggests that some on Wall Street believe the company's broader pipeline remains promising despite the setback in rheumatoid arthritis.

Focus Shifts to Upcoming Catalysts

Spyre Therapeutics emphasized that the data helps validate TL1A inhibition as a mechanism and supports the drug's potential in other autoimmune diseases or as part of a combination therapy. The company's focus now shifts to several other upcoming data readouts from its pipeline.

Investors will be closely watching for further results, including:

  • Phase 2 SKYWAY data for SPY072 in psoriatic arthritis and axial spondyloarthritis, expected in the fourth quarter.
  • Additional data from its SKYLINE ulcerative colitis program, which is due in September.

The market is now repricing Spyre's near-term prospects following the rheumatoid arthritis news, with the stock's future performance likely hinging on the success of these remaining clinical milestones.

Read next

More on Stocks
Back to latest news

LATEST